We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.46 | -0.93% | 49.00 | 42.19 | 50.80 | 49.595 | 48.97 | 49.48 | 1,113,911 | 05:00:11 |
From May 2019 to May 2024
By Kimberly Chin
Regeneron Pharmaceuticals Inc. (REGN) and Sanofi SA (SAN.FR) said a European regulatory panel had issued a positive opinion and recommended conditional approval for their drug that treats patients with a common type of skin cancer.
If the drug, Libtayo, wins approval from the European Commission, it would be the first and only treatment for some patients with an advanced form of carcinoma in Europe.
Libtayo, which is jointly developed by Regeneron and Paris-based Sanofi, is a prescription medicine that treats carcinoma patients with who cannot be cured by surgery or radiation.
The companies said they will need to provide regulators with additional data from a new group trial to help confirm the benefits and risk profile of the drug.
European regulators could make a final decision on Libtayo within the coming months, the companies said.
Shares of Regeneron were down 2.5%, while shares of Sanofi rose 3.5% on Friday.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
April 26, 2019 12:33 ET (16:33 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
